Data verified by Bookimed as of December 2025, based on patient requests and official quotes from 24 clinics worldwide. Median costs are based on real invoices (2024–2025) and updated monthly. Actual prices may vary.
Hisar Hospital Intercontinental is a multi-specialty medical center in Istanbul, Turkiye, accredited by the Joint Commission International (JCI) for meeting high standards of treatment quality and safety.
The hospital specializes in oncology, hematology, cardiovascular surgery, orthopedics, and bariatric procedures, including gastric sleeve, bypass, and balloon. It also offers comprehensive health check-ups.
Annually, over 500,000 patients seek medical care at Hisar Hospital Intercontinental. Patients from Europe, America, Africa, CIS, and the Balkans choose the hospital for specialized and high-quality treatment.
Dr. Mustafa Solak is a medical oncologist with expertise in breast, testicular, ovarian, lung, head-neck, and gastrointestinal cancers. He graduated from Hacettepe University School of Medicine. He completed his residency at Istanbul Sisli Etfal Teaching and Research…
Dr. Ofer Merimsly is the best sarcoma, lymphoma, and lung cancer doctor within Israel and in the world. Also specializes in Whipple surgery treatment for patients with pancreatic cancer. Head of the National Center for sarcomas of bone and soft tissues of the Tel Aviv…
Memorial is more than a hospital. It is home from home. Very hospitable and caring staff who show a lot of empathy. My one night stay in the hospital was a delightful experience, kind and available staff, every neat and hygienic room. The doctors are on top of their job. I was taken through a lecture in nuclear physics 101, broken in simple language. The lecturer helped allayed my initial fears about the treatment. The treatment was speedy and the results came so quickly. The doctor was by my bedside to explain the next steps. The translator was fantastic. The transportation service was superb, always on time. I got more than value for my money. I will strongly recommend Memorial Sisli Hospital for any person seeking Lu-177 therapy
The ever presence of the medical support to attend to me in deep into the night.
May be the food could be improved in terms of quality served
About Bookimed service
Bookimed is a fantastic service organisation. Very quick on follow ups and providing feedback. They connect you the all relevant personnel from visa acquisition to hospital appointment promotly. Even when one arrives at the treatment facility they follow up to enquire if one has an challenges
A certified medical writer with 10+ years of experience, developed Bookimed’s trusted content, backed by a Master’s in Philology and medical expert interviews worldwide.
General practitioner. Winner of 4 scientific awards. Served in Western Asia. Former Team Leader of a medical team supporting Arabic-speaking patients. Now responsible for data processing and medical content accuracy.
This page may feature information relating to various medical conditions, treatments, and healthcare services available in different countries. Please be advised that the content is provided for informational purposes only and should not be construed as medical advice or guidance. Please consult with your doctor or a qualified medical professional before starting or changing medical treatment.
Fast Facts about Lutetium-177 therapy
Lutetium-177 therapy
Lutetium-177 therapy is a targeted radiotherapy utilizing the Lutetium-177 radioisotope to treat certain cancers effectively.
Pros: Offers a high degree of precision, minimizing damage to healthy tissues. Demonstrates a favorable response rate in 60% of patients with neuroendocrine tumors.
Cons: Not suitable for all cancer types. Requires rigorous patient selection and monitoring due to potential kidney toxicity.
Effectiveness: Achieves 30-40% reduction in tumor size for responsive patients.
Duration: 1-2 hours per session.
Recovery: Initial recovery period of 1-2 days, with full recovery taking a few weeks.
Best for: Neuroendocrine tumors and prostate cancer with specific receptor expression.
Lutetium-177 therapy is an innovative and targeted prostate cancer treatment for patients with advanced prostate cancer, especially those with metastatic prostate cancer. “Targeted” means that the treatment specifically seeks out and binds to prostate cancer cells while avoiding nearby healthy tissues.
🔹This treatment uses nuclear medicine to deliver radiation directly to prostate cancer cells, helping manage disease progression. This method gives hope when other prostate cancer treatments have not been effective.
What is Lutetium 177?
It’s a radioactive substance that binds to PSMA (prostate-specific membrane antigen), which is present in high amounts on tumor cells. This allows Lutetium-177 to deliver targeted radiation, destroying cancer cells while sparing the healthy tissues. This approach leads to fewer adverse events than traditional hormonal therapies and other treatments.
✅Patients treated with Lutetium-177 treatment for prostate cancer often experience improved progression-free survival and a higher chance of living longer with fewer symptoms. The lutetium 177 success rate has been encouraging, showing that many patients respond well, even in cases of castration-resistant prostate cancer.
This therapy is part of treatment regimens recommended for patients needing a powerful alternative to first-line treatment options.
How Does Lutetium-177 Treatment Work for Prostate Cancer?
Facing advanced prostate cancer is overwhelming, especially when other treatment options have not brought the hoped-for results. But there is hope in Lutetium-177 therapy. This innovative approach consists of the following stages:
Step
Description
1. Clinical examination
The patient undergoes a thorough examination and review of medical reports to assess suitability for the treatment.
2. Blood tests
Blood tests are performed to ensure the patient’s liver and kidney functions are normal, as these organs help process the treatment.
3. Injection of radiopharmaceutical
A doctor injects radiopharmaceutical containing Lutetium-177 into the patient’s vein. This substance accumulates specifically in tumor cells, minimizing damage to healthy tissues.
4. Targeting cancer cells
The radiopharmaceutical travels through the bloodstream and binds to PSMA on prostate cancer cells.
5. Delivering radiation
Lutetium-177 releases radiation directly to the cancer cells, effectively destroying them while sparing nearby healthy tissues.
6. Monitored stay
The patient stays in a screened ward for a short period to ensure safety and monitor any immediate reactions.
Effectiveness of Lutetium-177 Therapy for Metastatic Prostate Cancer
Lutetium-177 therapy is a powerful treatment for advanced prostate cancer. It works well, even for patients whose cancer has spread and who have tried many other treatments.
🔹A study by Hofman and his team showed excellent results. Over half of 30 patients treated had their PSA levels drop by 50% or more. This means their cancer responded well. Most patients felt better by the second treatment cycle. There were no deaths from the treatment, and side effects like dry mouth, nausea, and tiredness were usually mild.
🔹Another study by Rahbar included 145 patients. Nearly half of them had a big drop in PSA levels after their treatment. Some patients felt better after just one session. While a few had side effects like anemia or low blood counts, these were manageable. This study showed that Lutetium-177 therapy works better and is safer than many other treatments for hard-to-treat prostate cancer.
🔹The VISION trial was even bigger. It included over 800 patients. Those who got Lutetium-177 therapy lived longer and had more time before their cancer grew. Patients treated with this therapy had a median of 8.7 months before their cancer got worse, compared to just 3.4 months for those who didn't get it. They also lived around four months longer overall. Some side effects were stronger in this group, but most patients handled them well.
Is This Treatment Safe?
In conclusion, lutetium 177 life expectancy outcomes are promising for patients with advanced prostate cancer, particularly those with metastatic castration-resistant types.
A review of several studies showed a biochemical response rate of 45%, with 40% of patients responding after only one treatment cycle. In another analysis, 65% of patients experienced a PSA reduction of more than 50%, and 23% had a reduction of over 90% after multiple treatment cycles.The lutetium 177 success rate is impressive, with studies showing effective targeting of cancer cells.
Lutetium-177 Treatment Costs Across The Globe
The lutetium-177 treatment cost UK and Germany are among the highest, reaching up to $44,000 and $45,000, respectively. In contrast, Turkey offers lu 177 treatment at a significantly lower cost, ranging from $6,500 to $13,000. This represents potential savings of up to $32,000, which is about 71% less than the highest lutetium psma therapy cost in Germany or the UK.
Austria and Spain offer lutetium 177 treatment for prostate cancer at costs up to $35,000, providing savings of about 22% or $10,000 compared to the top prices in Germany and the UK.
🏷️For patients considering lutetium 177 treatment, seeking care in a country like Turkey can be an excellent way to reduce treatment costs while receiving high-quality care.
Lutetium-177 therapy packages are designed to make the treatment process stress-free for patients. These packages bundle essential services to simplify the medical journey.
✅Benefits of all-Inclusive packages
All-inclusive lutetium-177 therapy packages offer comprehensive care, providing patients with everything they need from start to finish. These packages often include medical procedures, accommodation, transport, and continuous support, making the experience more manageable and predictable.
What is included in a typical package?
Most Lutetium-177 therapy packages offer:
The therapy itself and medical consultations.
Preoperative and blood tests, plus follow-up exams like PET/CT scans.
Hospital stay (1-2 days) and several nights in a hotel.
Transport services (VIP or standard transfers).
24/7 assistance and a personal medical coordinator.
*Important to double-check what services are included into a specific deal.
✔️ Typically Included Services
✖️ Details to Clarify
Lutetium-177 therapy and consultations
Accommodation type and quality
Preoperative tests and blood tests
Specific transport options (VIP or standard)
Follow-up exams (e.g., PET/CT)
Scope of procedures and extra costs
1-2 days in the hospital and hotel stay
Duration of hospital/hotel stay
Transport services (e.g., VIP transfers)
Special services like priority appointments
24/7 assistance and medical coordinator
Medical travel arrangements and patient advocacy
❕The services in these packages can vary by country. Turkey is known for offering some of the most comprehensive Lutetium-177 therapy packages.
Who Can Get Lutetium-177 Therapy?
Lutetium-177 therapy is for people with advanced prostate cancer. It is especially for those whose cancer has spread and who have tried other treatments without success. Here’s who can get this therapy:
Confirmed cancer diagnosis. The person must have prostate cancer that is advanced or has spread.
PSMA-positive cancer. The cancer cells must have PSMA (prostate-specific membrane antigen) on them. A special scan checks for this. If PSMA is present, the treatment can find and target the cancer cells.
Tried other treatments. This therapy is for people who have already tried other treatments, like chemotherapy or hormone therapies, and didn’t get the results they needed.
Healthy organs. The liver and kidneys need to be working well. Blood tests help doctors check this.
Good overall health. The person must be healthy enough to handle the treatment.
🔹Patients receive this therapy at a comprehensive cancer center, where multidisciplinary teams provide advanced care and access to the latest clinical trials. Bookimed works only with varified clinics.
Treatment Options for Metastatic Prostate Cancer
When prostate cancer spreads to other parts of the body, it is called metastatic prostate cancer, which can be harder to treat. However, several treatment options are available to help control the disease and manage symptoms. Lutetium-177 therapy (also known as Lu-177 treatment) is a newer, promising approach, but other options are available as well.
Hormonal therapies. Many prostate cancer cells need testosterone, a male hormone, to grow. These hormonal therapies work by lowering testosterone levels in the body. With less testosterone, the cancer cells have less fuel to grow, which can slow disease progression.
Chemotherapy. This treatment uses powerful drugs that spread throughout the body to kill cancer cells wherever they are. It is often used when the cancer has spread far beyond the prostate.
Radiation Therapy. High-energy rays are directed at specific spots in the body to kill cancer cells in those areas. This targeted therapy can help reduce the size of tumors and control symptoms in certain places where the cancer has spread.
Lutetium-177 Therapy (Lu-177). Lutetium-177 therapy is a targeted therapy that uses a radioactive substance to attach to and destroy prostate cancer cells that have PSMA (Prostate-Specific Membrane Antigen) markers.
Surgery. In some cases, surgery may be performed to remove the prostate or to relieve specific symptoms caused by the cancer. Surgery is less common in metastatic cases, but it may still be an option depending on the situation.
Lutetium PSMA therapy cost vs other procedures
The lutetium-177 treatment cost varies widely based on country, but it is generally higher than traditional treatments due to its specialized nature. Below, we explore how lutetium 177 price compared to other treatments for metastatic prostate cancer.
Procedure
Austria
Germany
Israel
Spain
Turkey
USA
UK
Hormonal Therapies
$3,000 - $5,000
$2,800 - $4,500
$3,500 - $6,000
$3,000 - $5,500
$1,500 - $3,000
$4,000 - $7,000
$3,500 - $6,000
Chemotherapy
$3,500 - $5,500
$2,800 - $4,200
$4,000 - $7,000
$3,500 - $6,000
$2,000 - $4,000
$10,000 - $15,000
$6,000 - $10,000
Radiation Therapy
$5,000 - $8,000
$8,000 - $12,000
$7,500 - $10,000
$6,500 - $9,500
$4,500 - $7,500
$15,000 - $30,000
$10,000 - $15,000
Surgery
$15,000 - $25,000
$20,000 - $30,000
$20,000 - $35,000
$15,000 - $25,000
$10,000 - $20,000
$30,000 - $50,000
$20,000 - $35,000
Lutetium-177 Therapy
$16,000 - $35,000
$24,000 - $45,000
$25,000 - $40,000
$16,000 - $35,000
$6,500 - $13,000
$18,000 - $27,000
$26,000 - $44,000
Future of Lutetium 177 Therapy
The future of
177lu therapy is bright, with ongoing research and development aimed at enhancing its safety and efficacy. As more clinical trials are completed, Lu-177 therapy is expected to become a standard treatment option for patients with metastatic prostate cancer. Researchers are also exploring its potential applications in other types of cancer, such as thyroid cancer, and in combination with other treatments to boost its effectiveness.
From a cost-effectiveness perspective, Lu-177 therapy has shown notable clinical benefits and is considered cost-effective for patients with metastatic prostate cancer. A cost-effectiveness analysis highlighted its value from a healthcare system perspective, demonstrating that the therapy provides significant benefits relative to its costs. However, treatment costs can vary depending on the location and specific treatment protocols used.
Overall, Lu-177 therapy is a promising new treatment option for patients with metastatic prostate cancer. Its ability to target PSMA and destroy cancer cells makes it a valuable addition to the treatment landscape for this challenging disease.
References:
[ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study / M. S. Hofman et al. The Lancet Oncology. 2018. Vol. 19, no. 6. P. 825–833. URL: https://doi.org/10.1016/s1470-2045(18)30198-0 (date of access: 11.11.2024).
German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients / K. Rahbar et al. Journal of Nuclear Medicine. 2016. Vol. 58, no. 1. P. 85–90. URL: https://doi.org/10.2967/jnumed.116.183194 (date of access: 11.11.2024).
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer / O. Sartor et al. New England Journal of Medicine. 2021. Vol. 385, no. 12. P. 1091–1103. URL: https://doi.org/10.1056/nejmoa2107322 (date of access: 11.11.2024).
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review / K. Patell et al. Expert Review of Anticancer Therapy. 2023. URL: https://doi.org/10.1080/14737140.2023.2213892 (date of access: 11.11.2024).